High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil

Gorki Grinberg a, Leila Bertoni Giron a, Rosalie Kupka Knoll b, Juliana Galinskas a, Michelle Camargo a, Muhammad Shoaib Arif a, Sadia Samer a, Luiz Mario Ramos Janini a,c, Maria Cecilia Araripe Sucupira a, Ricardo Sobhie Diaz a,*

a Infectious Diseases Division, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
b Centro de Ciências da Saúde, Universidade do Vale do Itajai (UNIVALI), Itajai, SC, Brazil
c Microbiology Division, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

Abstract

Itajaí is a port city in southern Brazil with one of the highest incidence and mortality rates from AIDS in the country. The prevalence and incidence of HIV infection were investigated in 1085 of 3196 new HIV-1 infection cases evaluated in the counseling and testing center of Itajaí from January 2002 to August 2008. Recent infections were assessed using the BED™, and pol region sequencing was performed in 76 samples. The prevalence ranged from 3.08% to 6.17% among women and from 10.26% to 17.36% among men. A total of 17% of infections were classified as recent, with annual incidence varying from 1.6% to 4.8 per 100 patient/year among women and from 2.05% to 8.5 per 100 patient/year among men. Pol sequences were obtained from 38 randomly selected individuals: 71% were infected by subtype C, 24% B, 2% D, and 2% F1. Among 38 subjects with established infection, 76% were subtype C, and 24% B. Transmitted drug resistance was detected in 18.4% of recent infection subjects (7.8% to nucleoside analog reverse-transcriptase inhibitors, 5.2% to non-nucleoside reverse-transcriptase inhibitors, and 5.2% protease inhibitors) and 5.2% of subjects with established infection had nucleoside analog reverse-transcriptase inhibitors resistance.

The high prevalence and incidence of HIV infection in this region is unprecedented in studies involving cases evaluated in the counseling and testing centers in Brazil.

© 2015 Elsevier Editora Ltda. All rights reserved.
Introduction

From 1982 to June 2012, 656,701 cases of AIDS were reported in Brazil. Brazil is divided into five macroregions: north, northeast, midwest, southeast, and south. The southeast and south regions are the most economically developed and have the highest number of AIDS cases in the country. In contrast, the mortality rate from AIDS is higher in the poorer regions of the country. An interesting peculiarity has been reported in Itajaí, a city located in the state of Santa Catarina in southern Brazil. This port city, with approximately 185,000 inhabitants, often leads the ranks in the number of AIDS cases per 100,000 inhabitants and of mortality rates from AIDS.

Several studies have been conducted in Brazil to evaluate the genetic diversity of HIV-1 in the country and have revealed the presence of subtypes B, F, C, and a significant number of recombinant subtypes. Subtype B virus is the most prevalent throughout the country, whereas subtype C virus and its recombinant forms are highly prevalent in southern Brazil. The prevalence of transmitted drug resistance (TDR) to antiretroviral agents in Brazil is considered moderate, typically ranging from 5% to 10%.

In this study, we analyzed the prevalence and incidence of HIV-1 infection in a counseling and testing center (CTC) in Itajaí to gain further insight into the high incidence of AIDS and high HIV-related mortality.

Materials and methods

This is a retrospective analysis evaluating stored sera samples and data registered in medical files. From January 2002 to August 2008, we evaluated 1085 patients from the CTC in Itajaí who were diagnosed with HIV-1. The patients had never used antiretroviral drugs, and HIV serology was confirmed with two ELISA tests and western blotting. Serum samples were sent to the Retrovirology Laboratory at the Federal University of São Paulo, where further laboratory tests were performed. The study was approved by the Institution’s Research Ethics Committee.

To determine recent infection (RI), the AWARE™ BED™ EIA HIV-1 incidence test was used according to the manufacturer’s instructions, and the incidence was calculated according to previously established guidelines.

To determine the HIV-1 subtypes and the occurrence of TDR, 38 samples were randomly selected from subjects with RI and 38 samples from subjects with established infection (EI). All samples were processed as previously described. TDR was evaluated according to an algorithm that excludes common polymorphisms. The profile of HIV-1 subtypes was determined using REGA HIV-1 Subtyping tool version 2.0 (http://www.bioafrica.net/rega-genotype/html/index.html).

For statistical analysis, calculations were performed to determine the prevalence and estimated incidence rates of infection. Moreover, parametric and nonparametric distribution tests, as well as descriptive analyses, were performed.

Results

Between January 2002 and August 2008, 41,115 subjects visited the CTC in Itajaí. Among them, 3196 subjects had positive HIV serology, and 1085 subjects were enrolled in the study. The prevalence and incidence rates of HIV infection according to year and gender are shown in Table 1.

New cases of HIV-1 infection during the study period were diagnosed through serological testing of the biological material provided by the CTC in Itajaí, state of Santa Catarina (SC). Male/female ratios obtained were 1.4:1 in 2002, 1.1:1 in 2003, 1:1 in 2004, 1.3:1 in 2005, 1:2:1 in 2006, 1:2:1 in 2007, and 1:4:1 in 2008. In 2008, the ratio was estimated proportionately because data were collected only until August.

Of the 1085 patients enrolled in the study, 519 (48%) were women, among whom 40 (8%) were pregnant. Their age ranged from 1.8 to 76 years, with a mean age of 34.9 ± 11.16 years and a median age of 34 years.

Regarding sexual orientation, 834 (81%) subjects were heterosexuals, 35 (3%) male homosexuals, 14 (1%) bisexual, and 150 (15%) did not answer the question. Furthermore, 785 (72%) subjects reported having acquired HIV through sexual intercourse: 33 (3%) through blood transfusion, 63 (6%) through injection drug use (IDU), 44 (4%) by vertical transmission, 2 (0.2%) through exposure to HIV-contaminated biological material, and 156 (14%) did not answer the question. Regarding the number of sexual partners per year, 10 (1%) respondents reported having no partners in the last year; 626 (61%) had 1 partner; 21 (1%) had 2 partners; 106 (10%) had 3 partners; 36 (3%) had 4–10 partners; 30 (3%) had more than 10 partners; and 204 (20%) did not answer the question. Regarding use of condoms, 488 (62%) reported not having used condoms; 148 (19%) reported sporadic use; 104 (13%) reported use of condoms in all sexual relations; and 45 (6%) did not answer the question.

Concerning HIV-1 subtypes among people with RI, 9 subjects (24%) were infected by subtype B, 27 (71%) by subtype C, 1 (2%) by subtype D, and 1 (2%) by subtype F1. Among the subjects with EI, 9 (24%) were infected by subtype B, and 29 (76%) by subtype C.

The prevalence of TDR was 18.4% (7 subjects, 95% CI: 8.3–34.9) among subjects with RI, of which 3 (7.8%) subjects had virus resistant to nucleoside reverse transcriptase inhibitors (NRTI; including mutations M41L, T215S, D67N, K70R, K219Q, and L210W), 2 (5.2%) were infected by virus resistant to non-nucleoside reverse transcriptase inhibitors (NNRTI; mutations Y181C and G190E), and 2 (5.2%) had viral resistant to protease inhibitors (PI; mutations V82A and I47V).

Among subjects with EI, the prevalence of TDR was 5.2% (2 subjects, 95% CI: 0.9–19.1), both of which had resistance to NRTI (mutations M41L, T215S, D67N, T69D, and K219Q).

There were no significant gender, age, level of education, epidemiology of HIV acquisition, HIV subtypes, and TDR differences.

Discussion

This study reports an unprecedented high prevalence and incidence rates of HIV infection in Brazil (Table 2). Furthermore, it
Table 1 – Prevalence and incidence among males and females from 2002 to 2008.

| Year | Female prevalences | 95% CI | Male prevalences | 95% CI | Total prevalence | 95% CI | Female incidence (per 100 PY) | 95% CI | Male incidence (per 100 PY) | 95% CI | Total incidence (per 100 PY) | 95% CI |
|------|-------------------|--------|-----------------|--------|-----------------|--------|-----------------------------|--------|-----------------------------|--------|-----------------------------|--------|
| 2002 | 6.00%             | 5.30–6.70 | 17.36%          | 15.56–19.16 | 10.67%          | 9.83–11.51 | 4.08                         | 2.38–7.78 | 8.50                         | 5.50–11.50 | 4.34                         | 3.18–5.50 |
| 2003 | 6.17%             | 5.47–6.87 | 14.34%          | 12.74–15.94 | 9.54%           | 8.78–10.3  | 2.42                         | 1.32–3.52 | 3.71                         | 1.41–6.01 | 2.83                         | 1.79–3.87 |
| 2004 | 4.26%             | 3.73–4.79 | 10.26%          | 8.93–11.59  | 6.54%           | 5.95–7.13  | 1.60                         | 0.20–3.44 | 2.05                         | 0.09–4.01 | 1.98                         | 0.04–3.92 |
| 2005 | 4.50%             | 3.93–5.07 | 11.75%          | 10.35–13.15 | 7.49%           | 6.84–8.14  | 1.60                         | 0.20–3.44 | 2.05                         | 0.09–4.01 | 1.98                         | 0.04–3.92 |
| 2006 | 4.02%             | 3.57–4.47 | 10.39%          | 9.26–11.52  | 6.56%           | 6.04–7.08  | 2.66                         | 1.42–3.90 | 4.96                         | 2.26–7.66 | 3.44                         | 2.21–4.67 |
| 2007 | 4.37%             | 3.86–4.88 | 11.05%          | 9.78–12.32  | 7.03%           | 6.45–7.61  | 3.17                         | 1.45–4.89 | 7.50                         | 4.04–10.96 | 4.23                         | 2.74–5.72 |
| 2008 | 3.08%             | 2.62–3.54 | 10.29%          | 9.13–11.45  | 5.51%           | 4.92–6.10  | 2.79                         | 1.65–3.93 | 7.80                         | 3.98–11.62 | 4.33                         | 3.64–5.02 |

CI, confidence interval.
| References          | Year | Period (years) | n  | RI            | Prevalence | Female prevalence | Male prevalence | Total incidence (per 100 PY) | 95% CI          | Female prevalence (per 100 PY) | Male prevalence (per 100 PY) |
|---------------------|------|----------------|----|---------------|------------|-------------------|-----------------|-----------------------------|----------------|--------------------------------|-------------------------------|
| Alves et al<sup>15</sup> | 2003 | 4              | 350| 36 (10.2%)    | 7.10%      | 5.10%             | 9.10%           | 2.00                        | 1.1–3.5%        | 1.20                           | 2.70                          |
| de Freitas Oliveira et al<sup>16</sup> | 2005 | 11             | 106| 18 (17%)      | 7.50%      | NA                | NA              | 0.20                        | 0.041–0.608%    | NA                             | NA                           |
| Mercon et al<sup>17</sup> | 2009 | 0.92           | 553| 47 (8.5%)     | 3.20%      | 2.1%              | 4%              | 1.39                        | 1.19–1.59%      | NA                             | NA                           |
| Bassichetto et al<sup>18</sup> | 2009 | 0.50           | 194| 29 (15%)      | 4.80%      | NA                | NA              | 0.53                        | 0.31–0.85%      | 0.22                           | 0.53                          |
| de Castro et al<sup>19</sup> | 2010 | 1              | 434| 61 (14%)      | 1310.00%   | 0.87%             | 2.80%           | 1.31                        | 0.61–0.86%      | 0.55                           | 1.34                          |
| Lima et al<sup>20</sup> | 2011 | 3              | 375| 105 (28%)     | 7.10%      | 5.10%             | 9.10%           | 2.00                        | 1.1–3.5%        | 1.20                           | 2.70                          |
corroborates important findings regarding the feminization of the HIV epidemic in the country. It has been reported that, in general, the ratio of infected men/infected women has decreased from 26.3/1 in the mid-1980s to approximately 1.5/1 in more recent years.\(^1\)

Overall, the demographic profile of the subjects being evaluated in the CTC of Itajai is similar to that found in other existing CTCs in Brazil (data not shown). The subtype profile of the study group revealed a high prevalence of subtype C virus, which is in agreement with previous studies, demonstrating the high prevalence of this subtype in southern Brazil.\(^3\) Similarly, the prevalence of TDR and the mutation profile in this small sample are in line with previous studies conducted in other regions of Brazil.\(^5\)

We acknowledge that tests for detecting recent infections, such as the BED assay, may eventually present flaws\(^6,9-11\) and validation studies using subtype C virus are scarce.\(^12-14\)

Moreover, we recognize that the number of subjects tested to determine viral subtypes and TDR was limited in this study. However, it is of note that the high prevalence and incidence rates of HIV-1 infection in Itajai, a city with a known high prevalence of AIDS and HIV-related mortality, is unprecedented in Brazil. Therefore, efforts should be made to identify the causes of the problem, decrease the mortality rate from AIDS, and interrupt the transmission cycle. Furthermore, the profile of subjects with recent HIV-1 infection should be better characterized.

**Conflicts of interest**

The authors declare no conflicts of interest.

**References**

1. Boletim Epidemiológico HIV-AIDS [HIV-AIDS Epidemiological Bulletin]. AIDS-DST Ano I – n° 01 até semana epidemiológica 522 – dezembro de 2012 [AIDS-STD Year 1 – No. 1 until epidemiological week 52 – December of 2012]; 2012.

2. Brasil. Ministério da Saúde [Brazil. Ministry of Health]. Aids e Pauperização [AIDS and impoverishment]; 1999.

3. Brindeiro RM, Díaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS. 2003;17:1063–9.

4. Leal E, Martins LO, Janini LM, Diaz RS. Evolutionary dynamics of HIV-1 BF and CB recombinants and its parental counterparts in South America. Retrovirology. 2008;1:1–14.

5. Inocêncio LA, Pereira AA, Sucupira MC, et al. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc. 2009;12:20.

6. CDC. CDC HIV/AIDS science facts: using the BED HIV-1 capture EIA assay to estimate incidence using STARHS in the context of surveillance in the United States; 2007.

7. Sucupira MC, Caseiro MM, Alves K, et al. High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS. 2007;21:116–28.

8. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4:e4724.

9. McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses. 2006;22:945–52.

10. McDougal JS, Pilcher CD, Parekh BS, et al. Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS. 2005;19 Suppl 2:S25–30.

11. Priddy FH, Pilcher CD, Moore RH, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr. 2007;44:196–202.

12. Hargrove JW, Humphrey JH, Mutas a K, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS. 2008;22:511–8.

13. Laeyendecker O, Brookmeyer R, Mullis CE, et al. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses. 2012;28:1177–83.

14. Moyo S, LeCuyer T, Wang R, et al. Evaluation of the false recent classification rates of multia assay algorithms in estimating HIV type 1 subtype C incidence. AIDS Res Hum Retroviruses. 2014;30:29–36.

15. Alves K, Shafer RF, Caseiro M, et al. Risk factors for incident HIV infection among anonymous HIV testing site clients in Santos, Brazil: 1996–1999. J Acquir Immune Defic Syndr. 2003;32:551–9.

16. de Freitas Oliveira CA, Ueda M, Yamashiro R, Rodrigues R, Sheppard HW, de Macedo Brígido LF. Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in São Paulo, Brazil, from 1991 to 2002. J Clin Microbiol. 2005;43:1439–42.

17. Mercon M, Tuboi SH, Batista SM, et al. Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil. J Infect Dis. 2009;13:272–8.

18. Bassichetto KC, Bergamaschi DP, Oliveira SM, et al. Elevated risk for HIV-1 infection in adolescents and young adults in São Paulo, Brazil. PLoS ONE. 2008;3:e1423.

19. de Castro CA, Grinsztejn B, Veloso VG, Bastos FI, Piloto JH, Morgado MG. Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil. BMC Infect Dis. 2010;10:224.

20. de Lima KO, Salustiano DM, Coelho MR, Cavalcanti AM, Díaz RS, Lacerda HR. Incidence of recent human immunodeficiency virus infection at two voluntary counseling testing centers in Pernambuco, Brazil, from 2006 to 2009. J Clin Microbiol. 2012;50:2145–6.